Torsten O Nielsen

List of Publications by Citations

Source: https://exaly.com/author-pdf/8985565/torsten-o-nielsen-publications-by-citations.pdf
Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

104 papers	15,303 citations	42 h-index	114 g-index
114 ext. papers	17,797 ext. citations	8.2 avg, IF	5.99 L-index

#	Paper	IF	Citations
104	Supervised risk predictor of breast cancer based on intrinsic subtypes. *Journal of Clinical Oncology*, **2009**, 27, 1160-7	2.2	2866
103	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. *Clinical Cancer Research*, **2004**, 10, 5367-74	12.9	2156
102	Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. *Journal of the National Cancer Institute*, **2009**, 101, 736-50	9.7	1545
101	Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. *Journal of the National Cancer Institute*, **2011**, 103, 1656-64	9.7	1156
100	Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. *Clinical Cancer Research*, **2008**, 14, 1368-76	12.9	917
99	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616
98	A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. *Clinical Cancer Research*, **2010**, 16, 5222-32	12.9	546
97	Molecular characterisation of soft tissue tumours: a gene expression study. *Lancet, The*, **2002**, 359, 1301-7	4.0	484
96	An international Ki67 reproducibility study. *Journal of the National Cancer Institute*, **2013**, 105, 1897-906	9.7	398
95	CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. *Breast Cancer Research*, **2012**, 14, R48	8.3	290
94	Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. *BMC Medical Genomics*, **2015**, 8, 54	3.7	242
93	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. *Journal of Clinical Oncology*, **2008**, 26, 5697-704	2.2	230
92	Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. *BMC Cancer*, **2014**, 14, 177	4.8	199
91	PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. *BMC Medical Genomics*, **2012**, 5, 44	3.7	199
90	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. *Seminars in Cancer Biology*, **2018**, 52, 16-25	12.7	181
89	An international study to increase concordance in Ki67 scoring. *Modern Pathology*, **2015**, 28, 778-86	9.8	168
88	Emerging targets in cancer immunotherapy. *Seminars in Cancer Biology*, **2018**, 52, 39-52	12.7	164

87	Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. *Journal of Clinical Oncology*, **2006**, 24, 5637-44	2.2	159
86	Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. *American Journal of Pathology*, **2003**, 163, 1449-56	5.8	123
85	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. *Journal of Pathology*, **2016**, 238, 389-400	9.4	122
84	Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. *Cancer Cell*, **2015**, 28, 500-514	24.3	121
83	Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics. *Cancer Cell*, **2012**, 21, 333-47	24.3	116
82	Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. *Breast Cancer*, **2017**, 24, 3-15	3.4	107
81	Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy. *Cancer Discovery*, **2015**, 5, 124-34	24.4	107
80	Defining breast cancer intrinsic subtypes by quantitative receptor expression. *Oncologist*, **2015**, 20, 474-82	5.7	102
79	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. *Journal of the National Cancer Institute*, **2021**, 113, 808-819	9.7	95
78	Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients. *Breast Cancer Research and Treatment*, **2010**, 119, 53-61	4.4	90
77	Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. *Breast Cancer Research*, **2008**, 10, R86	8.3	90
76	Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. *Npj Breast Cancer*, **2016**, 2, 16014	7.8	86
75	The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice. *Journal of Pathology*, **2020**, 250, 667-684	9.4	83
74	Identification of a Low-Risk Luminal A Breast Cancer Cohort That May Not Benefit From Breast Radiotherapy. *Journal of Clinical Oncology*, **2015**, 33, 2035-40	2.2	79
73	PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). *Npj Breast Cancer*, **2016**, 2,	7.8	58
72	Ki67 reproducibility using digital image analysis: an inter-platform and inter-operator study. *Laboratory Investigation*, **2019**, 99, 107-117	5.9	56
71	The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma. *Cancer Cell*, **2018**, 33, 527-541.e8	24.3	55
70	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *Npj Breast Cancer*, **2020**, 6, 17	7.8	54

69	Advances in sarcoma diagnostics and treatment. *Oncotarget*, **2017**, 8, 7068-7093	3.3	51
68	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. *Modern Pathology*, **2019**, 32, 59-69	9.8	51
67	The prognostic effects of somatic mutations in ER-positive breast cancer. *Nature Communications*, **2018**, 9, 3476	17.4	51
66	Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas. *OncoImmunology*, **2020**, 9, 1747340	7.2	49
65	NY-ESO-1 (CTAG1B) expression in mesenchymal tumors. *Modern Pathology*, **2015**, 28, 587-95	9.8	47
64	A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. *Modern Pathology*, **2013**, 26, 1438-50	9.8	47
63	The epigenomics of sarcoma. *Nature Reviews Cancer*, **2020**, 20, 608-623	31.3	45
62	High-Risk Premenopausal Luminal A Breast Cancer Patients Derive no Benefit from Adjuvant Cyclophosphamide-based Chemotherapy: Results from the DBCG77B Clinical Trial. *Clinical Cancer Research*, **2017**, 23, 946-953	12.9	38
61	Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. *Histopathology*, **2019**, 75, 225-235	7.3	37
60	Development and Evaluation of a Pan-Sarcoma Fusion Gene Detection Assay Using the NanoString nCounter Platform. *Journal of Molecular Diagnostics*, **2018**, 20, 63-77	5.1	36
59	Translating gene expression into clinical care: sarcomas as a paradigm. *Journal of Clinical Oncology*, **2010**, 28, 1796-805	2.2	36
58	Microarray analysis of sarcomas. *Advances in Anatomic Pathology*, **2006**, 13, 166-73	5.1	34
57	TIM-3 expression in breast cancer. *OncoImmunology*, **2018**, 7, e1502128	7.2	34
56	Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development. *Current Oncology Reports*, **2019**, 21, 2	6.3	33
55	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. *Modern Pathology*, **2019**, 32, 1772-1785	9.8	33
54	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance). *Journal of the National Cancer Institute*, **2020**, 112, 737-746	9.7	30
53	The Prosigna gene expression assay and responsiveness to adjuvant cyclophosphamide-based chemotherapy in premenopausal high-risk patients with breast cancer. *Breast Cancer Research*, **2018**, 20, 79	8.3	29
52	Histone deacetylase 1 and 2 in mesenchymal tumors. *Modern Pathology*, **2012**, 25, 222-30	9.8	29

51	New Strategies in Sarcoma: Linking Genomic and Immunotherapy Approaches to Molecular Subtype. *Clinical Cancer Research*, **2015**, 21, 4753-9	12.9	28
50	The genomic landscape of epithelioid sarcoma cell lines and tumours. *Journal of Pathology*, **2016**, 238, 63-73	9.4	27
49	HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma. *PLoS ONE*, **2017**, 12, e0169407	3.7	26
48	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. *Breast Cancer Research and Treatment*, **2016**, 155, 483-90	4.4	24
47	How current assay approval policies are leading to unintended imprecision medicine. *Lancet Oncology, The*, **2020**, 21, 1399-1401	21.7	24
46	Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2017**, 3, e172085	13.4	23
45	B-crystallin Expression in Breast Cancer is Associated with Brain Metastasis. *Npj Breast Cancer*, **2015**, 1,	7.8	22
44	Death by HDAC Inhibition in Synovial Sarcoma Cells. *Molecular Cancer Therapeutics*, **2017**, 16, 2656-2667	6.1	21
43	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort. *Breast Cancer Research and Treatment*, **2020**, 179, 3-10	4.4	21
42	Cell Cycle-Dependent Tumor Engraftment and Migration Are Enabled by Aurora-A. *Molecular Cancer Research*, **2018**, 16, 16-31	6.6	18
41	Diagnostic value of next-generation sequencing in an unusual sphenoid tumor. *Oncologist*, **2014**, 19, 623-30	5.7	17
40	The FUS-DDIT3 Interactome in Myxoid Liposarcoma. *Neoplasia*, **2019**, 21, 740-751	6.4	15
39	Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. *Cancer Treatment Reviews*, **2020**, 91, 102115	14.4	15
38	CCR 20th Anniversary Commentary: The Development of Breast Cancer Molecular Subtyping. *Clinical Cancer Research*, **2015**, 21, 1779-81	12.9	14
37	Activating transcription factor 2 in mesenchymal tumors. *Human Pathology*, **2014**, 45, 276-84	3.7	12
36	Circular YAC vectors containing short mammalian origin sequences are maintained under selection as HeLa episomes. *Journal of Cellular Biochemistry*, **2000**, 76, 674-85	4.7	12
35	Detection of CSF1 rearrangements deleting the 3UTR in tenosynovial giant cell tumors. *Genes Chromosomes and Cancer*, **2020**, 59, 96-105	5	12
34	An mRNA Gene Expression-Based Signature to Identify FGFR1-Amplified Estrogen Receptor-Positive Breast Tumors. *Journal of Molecular Diagnostics*, **2017**, 19, 147-161	5.1	11

33	Clinicopathologic factors and nuclear morphometry as independent prognosticators in KIT-positive gastrointestinal stromal tumors. *Journal of Histochemistry and Cytochemistry*, **2008**, 56, 139-45	3.4	11
32	Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor types. *Modern Pathology*, **2020**, 33, 1753-1763	9.8	10
31	Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. *Laboratory Investigation*, **2016**, 96, 885-94	5.9	10
30	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. *Histopathology*, **2017**, 70, 185-194	7.3	10
29	Identification of cytotoxic agents disrupting synovial sarcoma oncoprotein interactions by proximity ligation assay. *Oncotarget*, **2016**, 7, 34384-94	3.3	10
28	Nestin expression in breast cancer: association with prognosis and subtype on 3641 cases with long-term follow-up. *Breast Cancer Research and Treatment*, **2018**, 168, 107-115	4.4	10
27	The Prosigna 50-gene profile and responsiveness to adjuvant anthracycline-based chemotherapy in high-risk breast cancer patients. *Npj Breast Cancer*, **2020**, 6, 7	7.8	9
26	Population-based Study of Prosigna-PAM50 and Outcome Among Postmenopausal Women With Estrogen Receptor-positive and HER2-negative Operable Invasive Lobular or Ductal Breast Cancer. *Clinical Breast Cancer*, **2020**, 20, e423-e432	3	9
25	HDAC2 Regulates Site-Specific Acetylation of MDM2 and Its Ubiquitination Signaling in Tumor Suppression. *IScience*, **2019**, 13, 43-54	6.1	9
24	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. *Npj Breast Cancer*, **2020**, 6, 15	7.8	8
23	High-Throughput Screening of Myxoid Liposarcoma Cell Lines: Survivin Is Essential for Tumor Growth. *Translational Oncology*, **2017**, 10, 546-554	4.9	8
22	Age-correlated protein and transcript expression in breast cancer and normal breast tissues is dominated by host endocrine effects.. *Nature Cancer*, **2020**, 1, 518-532	15.4	7
21	The ability of PAM50 risk of recurrence score to predict 10-year distant recurrence in hormone receptor-positive postmenopausal women with special histological subtypes. *Acta Oncologica*, **2018** , 57, 44-50	3.2	7
20	Basal biomarkers nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: Samples from the phase III SBG0102 clinical trial. *International Journal of Cancer*, **2019**, 144, 2578-2586	7.5	7
19	Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. *Clinical Cancer Research*, **2020**, 26, 2603-2614	12.9	5
18	Differential expression and prognostic relevance of autophagy-related markers ATG4B, GABARAP, and LC3B in breast cancer. *Breast Cancer Research and Treatment*, **2020**, 183, 525-547	4.4	5
17	Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune Checkpoints. *Cancers*, **2021**, 13,	6.6	5
16	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2021**, 185, 557-566	4.4	5

15	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. *Journal of Clinical Oncology*, **2015**, 33, 2594-2594	2.2	4
14	Discovery research to clinical trial: a ten year journey. *Clinical and Investigative Medicine*, **2010**, 33, E342-8	0.9	4
13	Phospho-Ser-VCP Is Required for DNA Damage Response and Is Associated with Poor Prognosis of Chemotherapy-Treated Breast Cancer. *Cell Reports*, **2020**, 31, 107745	10.6	4
12	A Rapid and Cost-Effective Gene Expression Assay for the Diagnosis of Well-Differentiated and Dedifferentiated Liposarcomas. *Journal of Molecular Diagnostics*, **2021**, 23, 274-284	5.1	4
11	Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials. *Acta Oncologica*, **2018**, 57, 135-140	3.2	4
10	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. *Nature Communications*, **2022**, 13, 896	17.4	4
9	Response to Zhang and Yang. *Journal of the National Cancer Institute*, **2021**, 113, 1597-1598	9.7	2
8	Proteomics-derived basal biomarker DNA-PKcs is associated with intrinsic subtype and long-term clinical outcomes in breast cancer. *Npj Breast Cancer*, **2021**, 7, 114	7.8	2
7	The immune microenvironment and relation to outcome in patients with advanced breast cancer treated with docetaxel with or without gemcitabine. *OncoImmunology*, **2021**, 10, 1924492	7.2	2
6	Competing Risks of Mortality by PAM50 Intrinsic Subtype of British Columbia Tamoxifen-Treated Cohort of Postmenopausal Patients With Breast Cancer. *Clinical Breast Cancer*, **2017**, 17, e215-e224	3	1
5	Role of intratumoral NK cells in triple-negative breast cancer in the FinXX trial and Mayo Clinic cohort.. *Journal of Clinical Oncology*, **2020**, 38, 510-510	2.2	0
4	Molecular profiling of ER weakly-positive breast cancer.. *Journal of Clinical Oncology*, **2015**, 33, 525-525	2.2	0
3	Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical Trials. *Clinical Cancer Research*, **2021** , 27, 6570-6579	12.9	
2	The association between ATG4B and HER2 status in breast cancer.. *Journal of Clinical Oncology*, **2016**, 34, e23275-e23275	2.2	
1	Synovial Sarcoma Oncogenesis Revealed by Single-Cell Profiling. *Trends in Cancer*, **2021**, 7, 482-483	12.5	